Payment overview · 2025
General Payments
$268.55
9 reported records · 6 companies
Healthcare provider profile · identity verified
Robert L. Savory, MD
Allopathic & Osteopathic Physicians|Family Medicine · SHREVEPORT, LA · NPI 1619968229
Verified facts
What the public records show
CMS Open Payments records show Robert L. Savory, MD received $268.55 in general payments during 2025 across 9 reported records.
Amgen Inc. accounted for 55.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $150.20 | 55.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.68 | 13.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.62 | 8.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.88 | 7.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.35 | 7.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.82 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $268.55 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $150.20 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $53.50 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $25.20 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $20.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
95 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 377 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 344 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 212 | 63 |
| Metformin Hcl | Metformin Hcl | 211 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 207 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 59 |
| Simvastatin | Simvastatin | 190 | 52 |
| Donepezil Hcl | Donepezil Hcl | 174 | 43 |
| Losartan Potassium | Losartan Potassium | 171 | 48 |
| Glipizide Er | Glipizide | 163 | 42 |
| Lisinopril | Lisinopril | 161 | 49 |
| Trazodone Hcl | Trazodone Hcl | 156 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 42 |
| Potassium Chloride | Potassium Chloride | 143 | 31 |
| Sertraline Hcl | Sertraline Hcl | 110 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 22 |
| Memantine Hcl | Memantine Hcl | 104 | 32 |
| Meloxicam | Meloxicam | 99 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 30 |
| Jardiance | Empagliflozin | 96 | 19 |
| Eliquis | Apixaban | 95 | 20 |
| Trulicity | Dulaglutide | 95 | 14 |
| Gabapentin | Gabapentin | 89 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 29 |
| Allopurinol | Allopurinol | 84 | 22 |
| Celecoxib | Celecoxib | 80 | 18 |
| Nifedipine Er | Nifedipine | 80 | 20 |
| Omeprazole | Omeprazole | 75 | 25 |
| Furosemide | Furosemide | 73 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 15 |
| Mounjaro | Tirzepatide | 62 | suppressed |
| Bumetanide | Bumetanide | 61 | 15 |
| Fosinopril Sodium | Fosinopril Sodium | 61 | 17 |
| Alprazolam | Alprazolam | 59 | 21 |
| Finasteride | Finasteride | 58 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 15 |
| Januvia | Sitagliptin Phosphate | 57 | 16 |
| Ezetimibe | Ezetimibe | 56 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 16 |
| Alendronate Sodium | Alendronate Sodium | 52 | 14 |
| Ozempic | Semaglutide | 50 | 12 |
| Clonazepam | Clonazepam | 48 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Carvedilol | Carvedilol | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | 16 |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Naproxen | Naproxen | 23 | 15 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 14 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 17 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Glimepiride | Glimepiride | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Primidone | Primidone | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $268.55 · 9 records | Amgen Inc. | FREESTYLE LIBRE 3, JARDIANCE, OTEZLA, REPATHA, REXULTI, SHINGRIX | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error